SEC Form D raise Raised $75M (Form D filed Jun 25, 2026); 4 roles open. SEC Form D 0001806540-26-000001 (Jun 25, 2026)Evidence (1 event)
Jun 25, 2026 · SEC Form D 0001806540-26-000001 Name of Issuer: Lycia Therapeutics, Inc.; CIK: 1806540; Address: South San Francisco, CA; Submission type: D; Filing date: 2026-06-25; Industry Group: Biotechnology; Date of First Sale: 2026-06-10; Types of Securities Offered: Equity; Business combination transaction: false; Total Offering Amount: 75000000; Total Amount Sold: 75000000; Federal exemptions: 06b
Raise Series D · $75M · announced Jun 25, 2026 Company release ↗Source quote
Jun 25, 2026 · Company release ↗ “– Lycia … company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases, today announced the completion of an oversubscribed $75 million Series D”
Raise Series C · $106.6M · announced May 13, 2024 Company release ↗Source quote
May 13, 2024 · Company release ↗ “Lycia … from financing to progress its lead programs into the clinic for autoimmune and inflammatory diseases SOUTH SAN FRANCISCO, CA, May 13, 2024 – Lycia Therapeutics, Inc., a leader in extracellular protein degradation, today announced the completion of an oversubscribed $106.6 million Series C”
Raises announced in these releases: $181.6M disclosed.
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
